What is the story about?
Shares of Akums Drugs will be in focus on Monday, December 22, after a large trade took place in the pre-open block window.
As many as 72.78 lakh shares or 4.62% of the outstanding equity of Akums Drugs changed hands in the block deal that took place in the block window.
The shares changed hands at an average price of ₹428 per share, which takes the total transaction value to ₹311.5 crore.
Buyers and sellers in the transaction are not immediately known.
Promoters of Akums Drugs had a 75.26% stake in the company at the end of the September quarter.
Among the public shareholders, Mutual Funds had a 6.44% stake, where Franklin India Opportunities Fund had a 4.18% stake in the company, while among Alternate Investment Funds (AIFs), Clarus Capital I has a 1.38% stake.
Close to 73,000 retail investors, or those with authorized share capital of up to ₹2 lakh, had a 4.6% stake in Akums Drugs as on September 30.
Ruby Qc Investment Holdings Pte. Ltd. had a 4.62% stake at the end of the September quarter. The firm had invested in the company during its IPO in 2024. The firm is associated with Quadria Capital.
Shares of Akums Drugs ended 1.4% higher on Friday at ₹428. The stock is down 32% so far in 2025 and are down 37% from their issue price of ₹679.
As many as 72.78 lakh shares or 4.62% of the outstanding equity of Akums Drugs changed hands in the block deal that took place in the block window.
The shares changed hands at an average price of ₹428 per share, which takes the total transaction value to ₹311.5 crore.
Buyers and sellers in the transaction are not immediately known.
Promoters of Akums Drugs had a 75.26% stake in the company at the end of the September quarter.
Among the public shareholders, Mutual Funds had a 6.44% stake, where Franklin India Opportunities Fund had a 4.18% stake in the company, while among Alternate Investment Funds (AIFs), Clarus Capital I has a 1.38% stake.
Close to 73,000 retail investors, or those with authorized share capital of up to ₹2 lakh, had a 4.6% stake in Akums Drugs as on September 30.
Ruby Qc Investment Holdings Pte. Ltd. had a 4.62% stake at the end of the September quarter. The firm had invested in the company during its IPO in 2024. The firm is associated with Quadria Capital.
Shares of Akums Drugs ended 1.4% higher on Friday at ₹428. The stock is down 32% so far in 2025 and are down 37% from their issue price of ₹679.
